What is he best known for?
The fields of study he is best known for:
Peter W. Mason mainly focuses on Virology, Virus, Flavivirus, Viral replication and Microbiology.
His primary area of study in Virology is in the field of Neutralizing antibody.
Virus connects with themes related to Virulence in his study.
His Flavivirus research includes themes of Interferon, Dengue virus and Recombinant virus.
His work deals with themes such as Vaccinia, Poxviridae and Orthopoxvirus, which intersect with Recombinant virus.
His studies deal with areas such as Coding region, Molecular biology, RNA interference, Host factor and Picornavirus as well as Viral replication.
His most cited work include:
- RNA interference screen for human genes associated with West Nile virus infection. (449 citations)
- Nonviral delivery of self-amplifying RNA vaccines (360 citations)
- Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. (277 citations)
What are the main themes of his work throughout his whole career to date?
Peter W. Mason focuses on Virology, Virus, Flavivirus, Antibody and Foot-and-mouth disease virus.
Specifically, his work in Virology is concerned with the study of Viral replication.
The Virus study combines topics in areas such as Molecular biology and Transfection.
His work carried out in the field of Flavivirus brings together such families of science as Interferon, Flaviviridae and Dengue virus, Dengue fever.
His Foot-and-mouth disease virus study combines topics in areas such as Complementary DNA and Foot-and-mouth disease.
The concepts of his Recombinant virus study are interwoven with issues in Vaccinia, Poxviridae, Orthopoxvirus and Humoral immunity.
He most often published in these fields:
- Virology (95.36%)
- Virus (73.20%)
- Flavivirus (35.05%)
What were the highlights of his more recent work (between 2012-2020)?
- Virology (95.36%)
- Virus (73.20%)
- Antibody (18.56%)
In recent papers he was focusing on the following fields of study:
Peter W. Mason mainly investigates Virology, Virus, Antibody, Immune system and Immunogenicity.
His study in Virology is interdisciplinary in nature, drawing from both Adjuvant and Antigen.
His Virus study integrates concerns from other disciplines, such as Reverse genetics and Genome.
The Monoclonal antibody, Epitope and Memory B cell research Peter W. Mason does as part of his general Antibody study is frequently linked to other disciplines of science, such as TLR3, therefore creating a link between diverse domains of science.
His Immune system research incorporates themes from RNA, Messenger RNA and Nucleic acid.
His Foot-and-mouth disease virus study combines topics from a wide range of disciplines, such as Cell culture, Recombinant virus and Active site.
Between 2012 and 2020, his most popular works were:
- Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics (152 citations)
- A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines (140 citations)
- Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice (118 citations)
In his most recent research, the most cited papers focused on:
Virology, Antibody, Virus, Immune system and Immunogenicity are his primary areas of study.
His biological study spans a wide range of topics, including Epitope, Antigen and Messenger RNA.
His study looks at the relationship between Epitope and topics such as Glycoprotein complex, which overlap with Neutralizing antibody.
His work in Antigen covers topics such as Human cytomegalovirus which are related to areas like Cytotoxic T cell, Viral entry, Glycoprotein, Pentamer and Alphavirus.
His work deals with themes such as RNA, Cell, Nucleic acid and Electroporation, which intersect with Messenger RNA.
His Hemagglutinin research is multidisciplinary, relying on both Neuraminidase, Synthetic vaccine, Influenza vaccine, Microbiology and Influenza A virus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
